Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

11/12/24 9:50:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $AVIR alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.6 ATEA PHARMACEUTICALS INC COMMON STOCK Cusip #04683R106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #04683R106 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 6,612,607 Item 6: 0 Item 7: 6,618,297 Item 8: 0 Item 9: 6,618,297 Item 11: 7.839% Item 12: HC Cusip #04683R106 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 6,618,297 Item 8: 0 Item 9: 6,618,297 Item 11: 7.839% Item 12: IN Item 1(a). Name of Issuer: ATEA PHARMACEUTICALS INC Item 1(b). Address of Issuer's Principal Executive Offices: 225 FRANKLIN STREET, SUITE 2100 BOSTON, MA 02110 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 04683R106 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 6,618,297 (b) Percent of Class: 7.839% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 6,618,297 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of ATEA PHARMACEUTICALS INC. No one other person's interest in the COMMON STOCK of ATEA PHARMACEUTICALS INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of ATEA PHARMACEUTICALS INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $AVIR alert in real time by email

Recent Analyst Ratings for

$AVIR

Date	Price Target	Rating	Analyst
8/13/2024	$2.00 → $6.88	Underweight → Equal-Weight	Morgan Stanley
8/10/2023		Neutral → Underweight	JP Morgan
3/2/2022	$10.00 → $8.00	Neutral	JP Morgan
3/1/2022	$10.00 → $9.00	Market Perform	SVB Leerink
2/16/2022	$11.00 → $10.00	Market Perform	SVB Leerink
1/6/2022	$14.00 → $7.00	Equal-Weight → Underweight	Morgan Stanley
11/18/2021		Outperform → Mkt Perform	SVB Leerink
11/18/2021	$11.00	Outperform → Market Perform	SVB Leerink

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

Chat with this insight

Recent Analyst Ratings for $AVIR

$AVIR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Kirsch Arthur S

New insider Kirsch Arthur S claimed ownership of 45,710 shares (SEC Form 3)

Chief Development Officer Hammond Janet Mj was granted 11,250 shares, covered exercise/tax liability with 14,134 shares and converted options into 46,800 shares, increasing direct ownership by 117% to 81,388 units (SEC Form 4)

$AVIR SEC Filings

Amendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.

SEC Form 10-Q filed by Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

$AVIR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Atea Pharmaceuticals upgraded by Morgan Stanley with a new price target

Atea Pharmaceuticals downgraded by JP Morgan

JP Morgan reiterated coverage on Atea Pharmaceuticals with a new price target

$AVIR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

$AVIR Press Releases

Fastest customizable press release news feed in the world

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

$AVIR Leadership Updates

Live Leadership Updates

Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

Atea Pharmaceuticals Appoints Nancy Gail Berry Agrawal, Ph.D., as Executive Vice President of Preclinical Development

$AVIR Financials

Live finance-specific insights

$AVIR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025

Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Amendment: Director Berger Franklin M bought $81,498 worth of shares (25,000 units at $3.26), increasing direct ownership by 6% to 476,897 units (SEC Form 4)

Director Berger Franklin M decreased direct ownership by 1% to 476,897 units (SEC Form 4)

Recent Analyst Ratings for
$AVIR

$AVIR
Insider Trading

$AVIR
SEC Filings

$AVIR
Analyst Ratings

$AVIR
Large Ownership Changes

$AVIR
Press Releases

$AVIR
Leadership Updates

$AVIR
Financials

$AVIR
Insider Purchases